Vaccination coverage in Asl CN2: historical trends on the 2012-2022 courts
DOI:
https://doi.org/10.14672/bepsp2024249-259Abstract
Vaccination is a key public health tool for public health in controlling infectious diseases, the ultimate goal of which remains the potential eradication of circulating pathogens. Since the World Health Organization (WHO) established the Expanded Immunization Program (EPI), an estimated 154 million deaths have been prevented, especially among children. Vaccines protect individuals and reduce global health and economic burdens while promoting herd immunity to safeguard vulnerable populations.
This report presents an analysis of vaccination coverage rates for the hexavalent vaccine and the measles, mumps, rubella (MMR) vaccine in the ASL CN2 district for birth cohorts from 2012 to 2022. Data for the 2017-2022 birth cohorts are derived from the Piedmont Region PADDI platform, and for the 2012-2016 cohorts from SEREMI annual reports. Hexavalent vaccine coverage showed slight growth before stabilizing above 95% for cohorts born from 2017 onward. MMR coverage, starting from a minimum of 89% for the 2013 cohort, exhibited more pronounced growth. Despite a slight decline in 2018 and 2019, coverage remained above the threshold for cohorts born from 2016 onward. Despite slight reductions during the COVID-19 pandemic, vaccination rates in the ASL CN2 were above the threshold for cohorts in the years covered by the “Lorenzin” Decree. Sustaining high vaccination rates is crucial for protecting vulnerable populations and preventing the resurgence of preventable diseases.
References
A. J. Shattock et al., «Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization», The Lancet, vol. 403, fasc. 10441, pp. 2307–2316, mag. 2024, doi: 10.1016/S0140-6736(24)00850-X.
P. Pezzotti et al., «The impact of immunization programs on 10 vaccine preventable diseases in Italy: 1900-2015», Vaccine, vol. 36, fasc. 11, pp. 1435–1443, mar. 2018, doi: 10.1016/j.vaccine.2018.01.065.
Ministero della Salute, Piano nazionale di prevenzione vaccinale (PNPV) 2023-2025. [Online]. Disponibile su: https://www.trovanorme.salute.gov.it/norme/dettaglioAtto?id=95963&completo=true
M. Sabbatucci, A. Odone, C. Signorelli, A. Siddu, F. Maraglino, e G. Rezza, «Improved Temporal Trends of Vaccination Coverage Rates in Childhood after the Mandatory Vaccination Act, Italy 2014-2019», J Clin Med, vol. 10, fasc. 12, p. 2540, giu. 2021, doi: 10.3390/jcm10122540.
C. Di Pietrantonj, A. Rivetti, P. Marchione, M. G. Debalini, e V. Demicheli, «Vaccines for measles, mumps, rubella, and varicella in children», Cochrane Database Syst Rev, vol. 2021, fasc. 11, p. CD004407, nov. 2021, doi: 10.1002/14651858.CD004407.pub5.
S. Marchi et al., «Measles immunity over two decades in two large Italian Regions: How far is the elimination goal?», Vaccine, vol. 39, fasc. 40, pp. 5928–5933, set. 2021, doi: 10.1016/j.vaccine.2021.08.001.
«Autismo. Tribunale di Rimini: “Colpa del vaccino”. Ministero condannato a pagare indennizzo - Quotidiano Sanità». Consultato: 2 dicembre 2024. [Online]. Disponibile su: https://www.quotidianosanita.it/regioni-e-asl/articolo.php?articolo_id=8363
N. Ramsay, H. Sidhu, e E. K. Waters, «Mathematics for medical practitioners and patients: Understanding how vaccines work for the community», Aust J Gen Pract, vol. 49, fasc. 5, pp. 293–294, mag. 2020, doi: 10.31128/AJGP-08-19-5038.
P. Fine, K. Eames, e D. L. Heymann, «“Herd Immunity”: A Rough Guide», Clinical Infectious Diseases, vol. 52, fasc. 7, pp. 911–916, apr. 2011, doi: 10.1093/cid/cir007.
R. Russo, E. Bozzola, P. Palma, G. Corsello, e A. Villani, «Pediatric routine vaccinations in the COVID 19 lockdown period: the survey of the Italian Pediatric Society», Italian Journal of Pediatrics, vol. 47, fasc. 1, p. 72, mar. 2021, doi: 10.1186/s13052-021-01023-6.
D. I. D. Lee et al., «Delay in childhood vaccinations during the COVID-19 pandemic», Can J Public Health, vol. 113, fasc. 1, pp. 126–134, feb. 2022, doi: 10.17269/s41997-021-00601-9.
A. Toss et al., «Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era», ESMO Open, vol. 6, fasc. 2, p. 100055, apr. 2021, doi: 10.1016/j.esmoop.2021.100055.
P. Giorgi Rossi et al., «The impact of the COVID-19 pandemic on Italian population-based cancer screening activities and test coverage: Results from national cross-sectional repeated surveys in 2020», eLife, vol. 12, p. e81804, doi: 10.7554/eLife.81804.
M. Sabbatucci et al., «Childhood Immunisation Coverage during the COVID-19 Epidemic in Italy», Vaccines (Basel), vol. 10, fasc. 1, p. 120, gen. 2022, doi: 10.3390/vaccines10010120.
J. Locke, A. Marinkovic, K. Hamdy, V. Balendra, e A. Sanyaolu, «Routine pediatric vaccinations during the COVID-19 pandemic: A review of the global impact», World J Virol, vol. 12, fasc. 5, pp. 256–261, dic. 2023, doi: 10.5501/wjv.v12.i5.256.
P. Muhoza et al., «Routine Vaccination Coverage - Worldwide, 2020», MMWR Morb Mortal Wkly Rep, vol. 70, fasc. 43, pp. 1495–1500, ott. 2021, doi: 10.15585/mmwr.mm7043a1.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
La rivista BE.PSP persegue la politica di sostegno alla circolazione delle idee e del sapere. Gli articoli in essa contenuti sono ad accesso libero e distribuiti secondo i termini della Creative Commons Attribution License: Attribution-NonCommercial-ShareAlike 4.0 International, CC BY-NC-SA. Questa licenza consente agli utilizzatori dei contenuti dell’articolo di distribuire, modificare, adattare e sviluppare il materiale originale su qualsiasi supporto o formato solo per scopi non commerciali, e solo a condizione che venga correttamente attribuita la paternità del materiale originale indicando l’autore dell’articolo originale. Se l'utente modifica, adatta o sviluppa il materiale, deve concedere in licenza il materiale modificato secondo termini identici.
